Salty Cravings with GLP-1 Receptor Agonists
GLP-1 receptor agonists do not cause increased salt cravings and do not affect sodium intake or salt craving scores in clinical studies. The appropriate response is reassurance and evaluation for alternative causes of this symptom.
Primary Evidence
The most direct evidence comes from a 2019 randomized clinical trial specifically examining this question 1. This study demonstrated that:
- Acute exenatide administration reduced sodium intake by up to 30% in parallel with overall reduced food intake, but this was a generalized reduction in all food consumption, not specific to sodium
- Prolonged liraglutide treatment (12 weeks) did not affect sodium intake or total caloric intake
- Neither acute nor prolonged GLP-1 RA therapy affected salt craving as measured by validated Likert scales
More recent prospective data from 2026 confirms these findings 2. In 28 adults followed for 24 weeks on semaglutide or tirzepatide, food cravings overall were unchanged, including no specific increase in salt cravings. The study used the Food Cravings Inventory-III questionnaire and found that higher baseline cravings were associated with reductions over time (r = -0.69, P < 0.001), not increases.
Clinical Framework for Evaluation
When a patient on GLP-1 therapy reports salt cravings, systematically evaluate:
1. Electrolyte Status (Priority)
- Check serum sodium immediately - A 2026 case report documents temporal association between tirzepatide and recurrent symptomatic hyponatremia 3
- This occurred particularly with concomitant thiazide-like diuretic use
- GLP-1 RAs increase renal sodium excretion, which could theoretically trigger compensatory salt-seeking behavior if sodium balance is disrupted
2. Medication Review
- Thiazide or thiazide-like diuretics (chlorthalidone, hydrochlorothiazide)
- Other medications affecting sodium balance
- Recent dose escalations of the GLP-1 RA itself
3. Volume Status Assessment
- Signs of dehydration or volume depletion
- Orthostatic vital signs
- Recent gastrointestinal symptoms (nausea, vomiting, diarrhea are common GLP-1 side effects 4)
4. Dietary Intake Pattern
- The 2026 CRAVE study showed significant reductions in total energy and micronutrient intake without structured nutrition support 2
- Patients may be inadvertently restricting overall intake, including sodium
- Higher protein intake was associated with better preservation of muscle mass (r = 0.41, P = 0.0498), suggesting dietary counseling is important
Management Algorithm
If serum sodium is low (<135 mEq/L):
- Consider dose reduction or temporary hold of GLP-1 RA
- Adjust or discontinue thiazide diuretics if present
- Monitor sodium closely with dose changes 3
If serum sodium is normal:
- Reassure the patient that GLP-1 RAs do not increase salt cravings
- Evaluate for other causes: adrenal insufficiency, pregnancy, psychological factors
- Consider whether the patient is experiencing altered food perception rather than true craving 5
- Provide nutrition counseling to ensure adequate overall intake
Important Caveats
The altered eating experience framework 5 suggests that patients may report "taste changes" or altered food preferences that are actually state-dependent food revaluation rather than true sensory changes. Salt cravings reported by patients may represent:
- Misattribution of other symptoms
- Response to reduced overall food intake
- Electrolyte disturbance from the medication's renal effects
Do not dismiss the symptom, but recognize it is not a direct pharmacologic effect of GLP-1 receptor stimulation on appetite regulation. The mechanism, if present, is likely indirect through sodium balance disruption rather than central craving pathways.